Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review
{{output}}
Purpose: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the BCR::ABL1 fusion oncogene. Asciminib, a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, represents a ... ...
